These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2655295)

  • 1. Intravenous erythromycin lactobionate-induced severe nausea and vomiting.
    Seifert CF; Swaney RJ; Bellanger-McCleery RA
    DICP; 1989 Jan; 23(1):40-4. PubMed ID: 2655295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal side effects of intravenous erythromycin: incidence and reduction with prolonged infusion time and glycopyrrolate pretreatment.
    Bowler WA; Hostettler C; Samuelson D; Lavin BS; Oldfield EC
    Am J Med; 1992 Mar; 92(3):249-53. PubMed ID: 1546723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Side-effects due to the intravenous infusion of erythromycin lactobionate.
    Putzi R; Blaser J; Lüthy R; Wehrli R; Siegenthaler W
    Infection; 1983; 11(3):161-3. PubMed ID: 6885176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of intravenous erythromycin lactobionate in respiratory infections.
    Di Sciacca A; Durante F; Cucchiara G; Ingrassia A; Mira G; Mannone F; Di Piazza RM; Frontini A; Barbagallo Sangiorgi G
    J Int Med Res; 1987; 15(4):245-50. PubMed ID: 3653502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically significant hearing loss in renal allograft recipients treated with intravenous erythromycin.
    Vasquez EM; Maddux MS; Sanchez J; Pollak R
    Arch Intern Med; 1993 Apr; 153(7):879-82. PubMed ID: 8466379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible sensorineural hearing loss with intravenous erythromycin lactobionate.
    Karmody CS; Weinstein L
    Ann Otol Rhinol Laryngol; 1977; 86(1 Pt 1):9-11. PubMed ID: 835977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible risk for cardiac arrhythmia related to intravenous erythromycin.
    Haefeli WE; Schoenenberger RA; Weiss P; Ritz R
    Intensive Care Med; 1992; 18(8):469-73. PubMed ID: 1289371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Jet intravenous injection of erythromycin lactobionate. A possible cause of the occurrence of crisis in torsade de pointe].
    Camilleri JF; Deharo JC; Panagidès D; Broin P; Mésana T; Blin D; Mouly-Bandini A; Dubouloz C; Goudard A; Montiès JR
    Ann Cardiol Angeiol (Paris); 1989 Dec; 38(10):657-9. PubMed ID: 2698118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of intravenous erythromycin lactobionate.
    Parsons RL; David JA; Raymond K; Stamp SM
    J Int Med Res; 1980; 8 Suppl 2():15-23. PubMed ID: 6968696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastrointestinal tract symptoms from intravenously administered erythromycin.
    Klika LJ; Goodman JM
    JAMA; 1982 Sep; 248(11):1309. PubMed ID: 7109149
    [No Abstract]   [Full Text] [Related]  

  • 11. Study of serum levels, venous irritation and gastrointestinal side-effects with intravenous erythromycin lactobionate in patients with bronchopulmonary infection.
    Marlin GE; Thompson PJ; Jenkins CR; Burgess KR; LaFranier DA
    Hum Toxicol; 1983 Oct; 2(4):593-605. PubMed ID: 6642516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tolerance and effectiveness of oral erythromycin ethyl succinate, intravenous Lactobionate and erythromycin base in infants and small children].
    Krepler P; Steinwenter A
    Arch Kinderheilkd; 1970 Jan; 180(2):129-50. PubMed ID: 5443953
    [No Abstract]   [Full Text] [Related]  

  • 13. Gastrointestinal side effects after intravenous erythromycin lactobionate.
    Downey KM; Chaput de Saintonge DM
    Br J Clin Pharmacol; 1986 Mar; 21(3):295-9. PubMed ID: 3964530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QT interval prolongation and torsades de pointes due to erythromycin lactobionate.
    Oberg KC; Bauman JL
    Pharmacotherapy; 1995; 15(6):687-92. PubMed ID: 8602374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac toxicity associated with intravenous erythromycin lactobionate: two case reports and a review of the literature.
    Farrar HC; Walsh-Sukys MC; Kyllonen K; Blumer JL
    Pediatr Infect Dis J; 1993 Aug; 12(8):688-91. PubMed ID: 8018130
    [No Abstract]   [Full Text] [Related]  

  • 16. Erythromycin lactobionate: pharmacokinetics and uterine tissue levels.
    Segui A; Milon D; Cormier M; Lepesant G
    Eur J Drug Metab Pharmacokinet; 1987; 12(3):153-60. PubMed ID: 3436337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin.
    Richards RD; Davenport K; McCallum RW
    Am J Gastroenterol; 1993 Feb; 88(2):203-7. PubMed ID: 8424421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiotoxicity of intravenous erythromycin lactobionate in the neonatal period].
    Gouyon JB; Betremieux T; Petion AM; Beneton C; Bavoux F
    Arch Fr Pediatr; 1991 May; 48(5):375-6. PubMed ID: 1859247
    [No Abstract]   [Full Text] [Related]  

  • 19. [Peroperative circulatory arrest after intravenous injection of erythromycin lactobionate].
    Hummel JC; Haberer JP
    Ann Fr Anesth Reanim; 1988; 7(1):85-6. PubMed ID: 3348523
    [No Abstract]   [Full Text] [Related]  

  • 20. QTc-interval prolongation associated with slow intravenous erythromycin lactobionate infusions in critically ill patients: a prospective evaluation and review of the literature.
    Tschida SJ; Guay DR; Straka RJ; Hoey LL; Johanning R; Vance-Bryan K
    Pharmacotherapy; 1996; 16(4):663-74. PubMed ID: 8840374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.